
|Articles|April 1, 2004
Oral Rx for stress incontinence closer to approval
Sydney, Australia--Duloxetine, a selective serotonin and norepinephrinereuptake inhibitor, yields significant improvements in incontinent episodesand quality of life among women with stress urinary incontinence, and ispoised to become the first effective oral agent for the condition, an Australianurologist says.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










